Bio.Be is the federation of Belgian companies active in the biosciences and is part of essenscia (chemicals and life sciences).
Bio.Be represents the interests of its members as regards legislation and standards at various policy levels (Belgium, EU, OECD).
Its mission is to create a stable legal framework in line with the trend for innovation, an essential factor for the economic sustainability and growth of employment in this sector.

To this end, Bio.Be keeps a close eye on:

  • policy in Belgium and organises consultation with the policymakers*;
  • European policy, as the national association contact point (NAC) of EuropaBio - the European biotechnology federation;
  • consultation on biotechnology within the OECD,
so that it is continuously able to establish benchmarks and anticipate the needs of its members.

Bio.Be can rely on the synergy within the essenscia group (product groups and and has access to the available expertise via the SME bureau; the patent unit, Invest in
biopharma, REACH, FISCH, BIOCHEM and CINBIOS projects and the extensive network of partners (VBO, VOKA, UWE, BECI, CEFIC, Business Europe).

* is also part of the high-level group essenscia/federal government and R&D biopharma platform/federal government

General assembly and seminar 19/04/2016


The General Assembly took place April 19 at the Square and welcomed the
new chair of, Mrs. Tineke Van hooland (ABBVIE). 
The GA thanked also Mr. Luc Kupers (Genzyme) for the years he was leading in an excellent way.
The GA endorsed the list of the Board members

After the GA, organized in cooperation with FBBF the seminar “Biotech meets Tech & Arts” about cross border cooperation as the new way forward in the world of innovation. Nanotech, smart materials, electronics, ICT, even the arts, are using biotech and vice versa.  We expect numerous breakthroughs in fields such as artificial intelligence, robotics, the Internet of Things, autonomous vehicles, 3-D printing, nanotechnology, biotechnology, (biobased) materials science, energy storage, and quantum computing. Engineers, scientists, designers, and architects are combining computational design, additive manufacturing, materials engineering, and gene technology to pioneer a symbiosis between microorganisms, plants, our bodies, the products we consume, and even the buildings we inhabit.

A closer look into the future developments of these innovations is necessary to see where we can learn from each other, to identify the needs in legislation, the possible hurdles and how to interact with society and politicians. The keys for bringing them to the market. We had excellent presentations from our Belgian and international keynote speakers about their views and experiences : Mr. Ralph Dum (EC), Mr. Jo De boeck (CTO IMEC), Mr. Wilfried Vancraen (CEO Materialise), Mrs. Athanassia Athanassiou (Instituto Italiano di Tecnologia Genova), Mr. Oron Catts (Director Symbiotica - Center of excellence in biological arts, University of Western Australia) and Mr. Christophe De Jaeger (Director Gluon, an Iminds/Bozar project).
Mr. Chris Burns (Euronews) moderated the panel debate with Mr. Paul Dujardin (Director BOZAR), Mrs. Elisabeth Monard (Honorary Secretary General FWO), Mr. Oron Catts (Director Symbiotica) and Mr. Enrico Bastianelli (CEO Bonetherapeutics). The new President of the Board, Mrs. Tineke Van hooland, closed the afternoon with some conclusions and thanked the speakers and the participants.

An exhibition by Ivan Henriques was organized by Gluon.


Board members

Name    Company
Tineke Van hooland ABBVIE (Chair)
Dirk Carrez Cleverconsult
Marleen Hoebus Amgen
Xavier Hormachea UCB
Elke Janssen NautaDutilh
Patrick Jeanmart Celyad
Luc Kupers Genzyme
Pascal Lizin GSK
Marc Martens Bird & Bird
Patrick Rüdelsheim Perseus
Annie Van Broekhoven Q Biologicals
Bert Van Loo Genencor/Dupont

Interaction with its members

Bio.Be interacts directly with its members though its three vertical working groups:
  1. Health or red biotechnology
  2. Agriculture or green biotechnology
  3. Biobased or white biotechnology
and through its horizontal working groups on ISO/CEN STANDARDS, INTELLECTUAL PROPERTY, START-UPS AND SMES. The positions adopted are passed on via the Bio.Be issue sheets**.

  • organises the training courses required, both for its members and for the relevant stakeholders.
  • promotes and represents its members in other relevant organisations and bodies at home and abroad.
  • cooperates with other federations, network organisations, academics and various other players and facilitates consultation among them.
**Cells and tissues (ATMPs, Hospital exemption), Clinical trials, Biosimilars, Orphan drugs; Coexistence, Low level presence, Implementing regulation, Socio-economic, Re-Nationalisation; Biofuels, Biomass, Waste legislation, Ecolab, Reach; ISO Biotechnology, CEN biobased, IP biotechnology, Strategy biobased economy.

The essenscia/ general assembly and seminar 18/02/14

The essenscia/ General Assembly and seminar (18.02.14) was a success. 7 political parties (OpenVLD, CD&V, Groen, NVA, CdH, MR, Ecolo) participated in the debate and explained their intentions about innovation and biotechnology. The debate was lead by Mr. Van Biervliet (VIB) and MR. De Kerpel (KBC Securities). Starting point were our Memorandum, Annual Report,  testimonials from our companies (see video below) and the presentations of  Deloitte (Scientific and Economic footprint of the Flemish Biotech), NautaDutilh (Belgian TTOs and their spin-offs. A match made in heaven?) and Biocom (The Biotech sector in Switzerland, Austria and Germany, a OECD study). This gave a good view of the current situation in Belgium and abroad, as well as what the policy should be to keep our biotech sector on the top level.